<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024422</url>
  </required_header>
  <id_info>
    <org_study_id>0053-21</org_study_id>
    <nct_id>NCT05024422</nct_id>
  </id_info>
  <brief_title>Lactation Inhibition, the Efficiency of Vitamin B6 Versus Cabergoline</brief_title>
  <official_title>Lactation Inhibition, the Efficiency of Vitamin B6 Versus Cabergoline- Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some mothers may seek lactation suppression on personal, social, or medical grounds. To&#xD;
      reduce congestion symptoms and shorten the duration of milk production lactation suppression&#xD;
      can be done pharmacologic or non-pharmacologic. The most common drug for this purpose is&#xD;
      Cabergoline, a dopaminergic agonist, that has significant side effects. Cabergoline is not&#xD;
      approved for use in patients with hypertensive disorders, fibrotic diseases, heart problems&#xD;
      or liver disease. Vitamin B6 has also been studied for this indication with no significant&#xD;
      side effects. All those studies conducted before 1980. There is no current literature on the&#xD;
      subject. There are no studies comparing Cabergoline to Vitamin B6 for this indication.&#xD;
&#xD;
      Purpose:&#xD;
&#xD;
      The aim of this study is to test whether Cabergoline is more effective than vitamin B6 for&#xD;
      lactation suppression.&#xD;
&#xD;
      method: A prospective randomized study in the maternity ward at Haemek medical center in&#xD;
      Afula, Israel.&#xD;
&#xD;
      Postpartum women without contraindication to any one of the treatments, who are interested in&#xD;
      a pharmaceutical induced lactation suppression will be divided into two randomized groups:&#xD;
&#xD;
        1. Administration of Cabergoline (one dose of 1mg, up to 24 hours postpartum, or 0.25 mg&#xD;
           twice a day for two days)&#xD;
&#xD;
        2. Administration of Vitamin B6 (200 mg X 3 per day for a week)&#xD;
&#xD;
      All women will answer a questionnaire to assess breast congestion, milk leakage and breast&#xD;
      pain on days 0, 2, 7 and 14.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lactation suppression</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>reduction of congestion</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cessation of milk leakage</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cessation of breast pain</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Lactation Suppressed</condition>
  <arm_group>
    <arm_group_label>Administration of Cabergoline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of Vitamin B6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg X 3 per day for a week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabergoline</intervention_name>
    <description>Administration of Cabergoline (one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days)</description>
    <arm_group_label>Administration of Cabergoline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridoxine</intervention_name>
    <description>Administration of Pyridoxine (200 mg X 3 per day for a week)</description>
    <arm_group_label>Administration of Vitamin B6</arm_group_label>
    <other_name>Vitamin B6</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Postpartum women who are interested in pharmacologic lactation suppression&#xD;
&#xD;
          2. Women over the age of 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women with known sensitivity to vitamin B6 or Cabergoline&#xD;
&#xD;
          2. Women with hypertensive Disorders or contraindication to Cabergoline.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adi Dayan Schwartz, MD</last_name>
    <phone>046495483</phone>
    <email>adi_da@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>HaEmek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Cabergoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

